March 15, 2021 7:44am
What will “juice” this market?
Pre-open indications: 7 BUYs and 1 SELL
Companies mentioned this a.m.: SELL: BSTG; BUY: ADVM, AGTC, BSTG, BLUE, CRSP, EDIT, FIXX, PSTI
News: bluebird bio (BLUE) announced new data from its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including updated results from the pivotal P2/3 Starbeam study (ALD-102) and the long-term follow-up study LTF-304, as well as safety outcomes from the P3 ALD-104 study.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Dow futures are UP +0.37% (+121 points), S&P futures are UP +0.22% (+9 points) and NASDAQ futures are UP +0.31% (+40 points)
U.S. stock futures traded slightly higher early Monday and pointed to a cautious open,
European stocks traded higher with the pan-European Stoxx 600 climbing +0.7% in early trading,
Asia-Pacific stocks lost momentum, paring some of their gains while many struggled to advance.
Data Docket: Investors will be gearing up for Tuesday and Wednesday’s Federal Open Market Committee meeting where the Federal Reserve will deliver its decision on interest rates.
Henry’omics:
The Nasdaq advanced 3% last week, while the small-cap benchmark Russell 2000 surged more than 7% last week as investors rotated into smaller stocks that benefit from a sharp economic comeback.
Let's get through the fed meeetings ... for markets and the sector can "click or get kicked' ...
Friday’s evening’s recap: “sector resistance rose as support degenerated, another I told you so” … https://www.regmedinvestors.com/articles/11811
- The Nasdaq closed DOWN -78.81 points (-0.59%),
- The IBB closed down -0.72% and XBI closed down -0.30%
- Sector volume was LOW with 2 of the 12-upside having higher than the 3-month average volume with the volume of 0 of 22-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -1.22 points or -5.57% at 20.69,
- Friday’s percentage (%) of the 12-upside were +0.08% (RARE) to +3.20% (KDNY) while the 22-downside ranges from -0.55% (ALNY) to -8.03% (BSTG);
March: 4 positive, 5 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell: Questions continue …
Biostage (BSTG) closed down again -$0.11 to $1.26 with 4,069 shares traded i.e., “pumped” after Thursday’s -$0.13 to 41.37 with 1,153 shares traded, Wednesday’s -$0.10 to $1.50 with 1,500 shares traded, Tuesday’s -$0.00 with 1,300 shares traded and last Monday’s -$0.03 to $1.60 with 6,200 shares traded (pumped re promoted”). Reiterating …
Question#1: WHY the need to “promote or pump” the share’s value, was or is this a directive from Jason Chen, the chairman of the board of BSTG to execute the outstanding warrants? Isn’t it securities fraud, a deceptive practice in the stock market that induces investors to make purchase or sale decisions on the basis of false information, frequently resulting in losses, in violation of securities laws? This “practice” also encompasses a wide range of other actions, including insider trading, front running and other illegal acts on the trading floor
Question#2: Isn’t that a possible felony and is Mrs. bin Zhao involved; could it be her account, DST Capital that these measures from or could be involved?
Question#3: Herman Sanchez, as a new BOD member, have you reviewed any circumstances of this “happening on your watch” and for the record; microcap fraud, stocks of small companies of under $250 million market capitalization are deceptively promoted, then sold to an unwary public. Microcap fraud includes pump and dump schemes ...
Question#4: Has RSM US LLP looked into the “matter” to make sure or that it actually is happening or NOT? Isn’t it unlawful for any person to transact business in Massachusetts as an investment adviser or he/she registered or “maybe” directing others to execute these so-called “promoting or pumping” trades? Review the daily volumes as the stock trades downward … questions exist?
MINORITY PUBLIC shareholders are waiting, watching and weighting responses to MAINTAIN their RIGHTS.
BUY:
Adverum Biotechnologies (ADVM) closed down -$0.50 to $10.67 with a positive +$0.27 or +1.53% aftermarket indication,
Applied Genetic Technologies (AGTC) closed down -$0.07 to $5.24 with a positive +$0.07 or +1.345 aftermarket indication,
bluebird bio (BLUE) closed up +$0.36 to $32.43 after Thursday’s -$0.41 to $32.07, Wednesday’s +$2.44 to $32.48, Tuesday’s $30.04, and last Monday’s $28.68 with a positive +$0.90 or +2.78% pre-market indication on news. Adrenoleukodystrophy (ALD) is a rare, X-linked metabolic disorder that is estimated to affect one in 21,000 male newborns worldwide. ALD is caused by mutations in the ABCD1 gene that affect the production of adrenoleukodystrophy protein (ALDP) and subsequently cause toxic accumulation of very long-chain fatty acids (VLCFAs) primarily in the adrenal cortex and white matter of the brain and spinal cord.
- Approximately 40% of boys with adrenoleukodystrophy will develop CALD, the most severe form of ALD, which is progressive and neurodegenerative, involving the breakdown of the nerve cells in the brain that are responsible for thinking and muscle control. CALD is associated with six MFDs, which severely compromise a patient’s ability to function independently: loss of communication, cortical blindness, need for tube feeding, total incontinence, wheelchair dependence, and complete loss of voluntary movement. CALD usually occurs in early childhood and progresses rapidly, if untreated, leading to severe loss of neurologic function, and eventual death, in most patients.
CRISPR Therapeutics (CRSP) closed down -$3.27 to $130.61 after Thursday’s +$9.73 to $133.88, Wednesday’s -$1.48 to $124.15, Tuesday’s +$12.03 to $125.63 and last Monday’s -$1.03 to $113.62 with a positive +$1.39 or +1.066% pre-market indication.
Editas Medicine (EDIT) closed down -$1.04 to $46.28 after Thursday’s +$0.66 to $47.32, Wednesday’s $46.66, Tuesday’s $45.33 and last Monday’s $40.54 with a positive +0.17 or +0.37% pre-market indication.
Homology Medicine (FIXX) closed down -$1.04 to $46.28 and has a positive +$0.79 or +8.01% aftermarket indication.
Pluristem (PSTI) closed down -$0.09 to $5.43 with a positive +$0.15 or +2.76% aftermarket indication.
The BOTTOM LINE: I see some bottom through the mist of momentum and algorithmic rules.
I STILL am a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim … if one can!”
Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
